Psychometric validation of the Chronic Ocular Pain Questionnaire (COP-Q)
Findings provide evidence that the COP-Q is a valid and reliable measure of patient-reported COSP symptoms and impacts for use in future clinical trials in COSP. Both 4-hour and 24-hour Symptom Module recall period versions are likely to yield consistent results and are equally robust.
Authors
- Christel Naujoks (ORCID: https://orcid.org/0000-0002-3799-6521)
- Michela Montecchi-Palmer (ORCID: https://orcid.org/0000-0001-5672-2481)
- Amy Findley (ORCID: https://orcid.org/0000-0001-9887-6956)
- Pedram Hamrah (ORCID: https://orcid.org/0000-0002-9313-2939)
- Paul O’Brien (ORCID: https://orcid.org/0000-0002-6064-8023)
- Rob Arbuckle (ORCID: https://orcid.org/0000-0003-0345-2523)
- A. Leventi (ORCID: https://orcid.org/0009-0007-6387-5874)
- Paul Karpecki (ORCID: https://orcid.org/0000-0003-1390-2532)
- Brigitte Sloesen (ORCID: https://orcid.org/0009-0003-5144-6678)
- Nicola Hodson (ORCID: https://orcid.org/0009-0004-5975-8032)
- Diana Plaza
- Ben Pascoe (ORCID: https://orcid.org/0009-0003-4454-1087)
Institutions
- Tufts University (US)
- Novartis (Switzerland) (CH)
- Tufts Medical Center (US)
- University of Pikeville (US)
- Adelphi Group (United Kingdom) (GB)
Publication Details
- Journal
- Journal of Patient-Reported Outcomes
- Published
- 2025-03-12
- DOI
- https://doi.org/10.1186/s41687-025-00862-9
- Citations
- 1
- Primary Topic
- Ocular Surface and Contact Lens
- Type
- article
- Field-Weighted Citation Impact
- 1.88
Funders
- Novartis Pharmaceuticals Corporation